Live Breaking News & Updates on Azn L

Stay updated with breaking news from Azn l. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FTSE rises ahead of Biden's budget | 28 May 2021


28 May 2021 | 12:02pm
StockMarketWire.com - The FTSE 100 was 0.35% higher at 7,044.36 as investors awaited details of president Biden s potential $6 trillion budget later.
Pharma giant AstraZeneca said Tagrisso had been approved in the European Union to treat patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer. The approval by the European Commission was based on positive results from the ADAURA phase 3 trial.
AstraZeneca s share price rose by 1.09% to £80.12.
Care-based housing and healthcare REIT Civitas Social Housing said it had completed the acquisition of 10 supported living properties across Hertfordshire, Essex, Suffolk and Wales for £8.6 million.
The properties are leased to Inclusion Housing Community Interest company, with rents adjusted annually in line with CPI over the full-term and are subject to a lower limit of inflation of 0% per annum and a maximum indexation of 4% per annum. ....

United Kingdom , City Of , Edinburgh Investment , Westminster Group , European Union , European Commission , Inclusion Housing Community Interest , Social Housing , Oxford Biometrics , Tritax Big Box Reit , Edinburgh Investment Trust , Share Index , Investment Trust , Astrazeneca Plc , Lon Azn , Azn L , Lon Csh , Lsh L , Bison Bag , Sag L , Lon Oxb , Oxb L , Lon Edin , Din L , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் ,

AstraZeneca's lung cancer treatment gets regulatory nod in EU | 28 May 2021


28 May 2021 | 07:13am
StockMarketWire.com - Pharma giant AstraZeneca said Tagrisso had been approved in the European Union to treat patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer.
The approval by the European Commission was based on positive results from the ADAURA phase 3 trial.
In the trial, adjuvant treatment with Tagrisso reduced the risk of disease recurrence or death by 83% in patients with Stage II and IIIA disease.
In the early stages of lung cancer, where tumour resection is possible but recurrence is far too common, adjuvant Tagrisso has shown an unprecedented disease-free survival benefit for patients with EGFR mutations, it added. ....

European Union , European Commission , Astrazeneca Plc , Lon Azn , Azn L , ஐரோப்பிய தொழிற்சங்கம் , ஐரோப்பிய தரகு ,